Introduction and Objective: While newly diagnosed type 2 diabetes (T2D) at the time of a stroke is associated with poorer outcomes, characteristics comparing individuals diagnosed with T2D during stroke hospitalization and those with previously established T2D are not very well documented. This study aimed to examine the differences between the two groups. Methods: This retrospective, observational cohort study included adults hospitalized with an ischemic stroke from 07/01/2017 to 03/31/2023 utilizing the PINC AI™ Healthcare Database. Descriptive statistics were used to compare sociodemographic and clinical characteristics during and after hospitalization among individuals with a T2D diagnosis or anti-diabetic medication use before hospitalization (estT2D) and those with a discharge T2D diagnosis or laboratory values indicating T2D during hospitalization without prior evidence of T2D diagnosis (newT2D). Results: Compared to those with estT2D (N=103,060), individuals with newT2D (N=127,286) were younger (mean±SD: 68.6±12.5 vs 71.0±12.5 years), more likely to be male (55.4% vs 49.3%) and less likely to be enrolled in Medicare (61.8% vs 74.8%). Individuals with newT2D had a lower Charlson comorbidity index (CCI) score (mean±SD: 4.7±2.1 vs 5.5±2.4) and were more likely to be in the highest quintile of social vulnerability index (23.5% vs 21.3%). Individuals with newT2D also had longer lengths of stay (mean±SD: 5.6±5.7 vs 5.2±5.0 days), higher all-cause mortality during hospitalization (4.4% vs 3.6%) and lower all-cause 30-day readmission post discharge (11.8% vs 16.6%), compared to those with estT2D. Conclusion: Individuals hospitalized with stroke and newT2D had lower CCI scores and 30-day readmission rates compared to those with estT2D. They also experienced longer hospital stays and higher inpatient mortality. Our results highlight the need for early diagnosis and management of T2D. C. Zhong: None. S. Emont: Other Relationship; Novo Nordisk. Employee; Premier, Inc. L. Xie: None. S. Ikpe: None. Z. Cao: Other Relationship; Novo Nordisk. Employee; Premier Inc. C.B. Lipkin: Employee; Premier Inc. J. Noone: Employee; Novo Nordisk. E. Zacherle: Employee; Novo Nordisk. C. Muhammad: Employee; Novo Nordisk. A. de Havenon: Consultant; Novo Nordisk.
Introduction and Objective: To assess the real-world effectiveness of oral sema on weight, BMI, and HbA1c outcomes among adults with T2D in the US, and compare it with DPP-4is. Methods: This observational study of adults with uncontrolled T2D (HbA1c ≥7%) initiating oral sema or DPP-4is (Oct 2019-Apr 2023; first prescription = index) used linked data from IQVIA PharMetrics® Plus adjudicated claims and Ambulatory Electronic Medical Records databases. Changes in weight, BMI and HbA1c outcomes from baseline to 6 months post-index were assessed for oral sema overall and in three subgroups: persistent (≤60-day gap in treatment), receiving dose ≥7 mg, and both persistent and receiving dose ≥7 mg. Furthermore, after inverse probability of treatment weighting (IPTW) for oral sema vs DPP-4is, a logistic regression model was used to evaluate adjusted outcomes. Results: In the overall oral sema sample (n=378) and subgroups, a significant mean reduction from baseline was seen in all outcomes (Figure). Post-IPTW, oral sema (n=259) was associated with significantly higher odds vs DPP-4is (n=486) in achieving composite post-index HbA1c <7% and ≥5% weight loss (odds ratio = 3.08; p<0.0001). Conclusion: Adults with T2D initiating oral sema had significant decreases in weight, BMI and HbA1c after 6 months, and higher odds of achieving the composite target vs DPP-4is. J. Amamoo: Employee; Novo Nordisk. R.P. Doshi: None. J. Noone: Employee; Novo Nordisk. L. Xie: None. M. Guevarra: Employee; Novo Nordisk. V. Divino: Employee; IQVIA Inc. J. Chen: None. A.A. King: None. Novo Nordisk Inc.
Introduction and Objective: This study aimed to examine changes in the 10-year Atherosclerotic Cardiovascular Disease (ASCVD) risk in patients treated with once-weekly subcutaneous semaglutide 2.4 mg in the real-world. Methods: Adult patients with overweight or obesity were identified from a large US claims and EMR database. Propensity score weighting was used to balance the characteristics between those who initiated semaglutide 2.4 mg from June 2021 to June 2023 and were treated for at least 12 months and those who did not initiate semaglutide 2.4 mg. The 10-year ASCVD risk score was calculated in those with assessment at baseline and 12 months using the AHA/ACC algorithm. Results: A total of 161 semaglutide 2.4 mg users and 43,578 non-users were included. After balancing, baseline characteristics were similar between the two cohorts. Semaglutide 2.4 mg users were 48.0 ± 9.6 yr, 75% women, while non-users were aged 48.7 ± 11.4 yr, 73% women. Among patients with BMI measurements at baseline and 12 months, the BMI of semaglutide 2.4 mg users (n=86) reduced from 38.6 kg/m2 at baseline to 33.1 kg/m2 at 12 months (a relative change of -14.2%), while the BMI for non-users (n=22,785) remained stable from 37.6 kg/m2 to 37.2 kg/m2. At 12 months, the proportion of patients in the intermediate-high-risk category (7.5% or above) of the ASCVD risk score decreased from 14.9% to 9.3% (an absolute change of -5.6% and a relative change of -37.5%) for the semaglutide 2.4 mg users, and increased from 17.7% to 18.7% (an absolute change of +1.0% and a relative change of +5.6%) for non-users. Conclusion: In adults with overweight or obesity, semaglutide 2.4 mg led to a reduction in ASCVD risk at one year based on AHA/ACC criteria, while in non-users, the risk slightly increased in the same time frame. This highlights the potential role of semaglutide 2.4 mg on ASCVD prevention in addition to clinically meaningful weight reduction in the real-world. A. Ruseva: None. M.E. Bassan: Employee; Novo Nordisk. Stock/Shareholder; Novo Nordisk. E.X. Du: Other Relationship; Novo Nordisk. A. Fabricatore: Employee; Novo Nordisk. Stock/Shareholder; Novo Nordisk A/S. B.O. Hartaigh: Employee; Novo Nordisk A/S. A. Manceur: Other Relationship; Novo Nordisk. W. Michalak: Employee; Novo Nordisk. Stock/Shareholder; Novo Nordisk A/S. R. Ramasubramanian: Other Relationship; Novo Nordisk. J. Song: Other Relationship; Novo Nordisk. Z. Zhao: Employee; Novo Nordisk. F. Lopez-Jimenez: Other Relationship; Anumana, Ultrasight, Anumana, Novo Nordisk.
Introduction and Objective: To assess prevalence and factors for treatment failure with SGLT2i in US adults with T2D. Methods: This was a retrospective cohort study among US adults with T2D who initiated SGLT2i between January 1, 2016 and April 30, 2024, using the Komodo Healthcare MapTM database. Treatment failure occurred if they discontinued SGLT2i, added or switched to another glucose-lowering therapy, or had consecutive HbA1c ≥8% without treatment changes. Time to SGLT2i failure was assessed using cumulative incidence functions. Factors for failure were identified using Cox models. Lastly, incidence of T2D complications and healthcare resource utilization (HCRU) were described. Results: Out of 237,295 new SGLT2i users, 183,485 (77.3%) experienced treatment failure over an average follow-up time of 34 months. The median time to failure was 9.14 months. Risk factors for failure included age ≥75, comorbidities such as hypertension, and experiencing common T2D-related adverse events such as hypoglycemia leading to ER or hospitalization. Lastly, high incidence of T2D complications and HCRU were observed with SGLT2i failure. Conclusion: The study revealed high prevalence and burden of treatment failure with SGLT2i, suggesting the need for timely treatment adjustment for the high-risk population who do not achieve optimal treatment benefit with SGLT2i. X. Tan: Employee; Novo Nordisk. Y. Cao: None. Y. Wang: Other Relationship; Analysis Group, Inc. J.M. Boland: None. M. Guevarra: Employee; Novo Nordisk. L. Xie: None. Y. Song: Research Support; Novo Nordisk. M.N. Kwak: Consultant; Novo Nordisk, Endocrine & Diabetes Plus Clinic of Houston. The study was funded by Novo Nordisk, Inc.